Fei Long

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Nguyen H. Tran, V. Libri, G. Screaton, 2021, The Lancet.

Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies.

D. Dimitrov, Yan Gao, B. Pang, 2020, Cancer cell.

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

V. Libri, S. Royal, J. Nguyen-Van-Tam, 2021, The Lancet.

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

V. Libri, S. Royal, G. Screaton, 2022, The Lancet Respiratory Medicine.

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

V. Libri, J. Nguyen-Van-Tam, S. Faust, 2021, Social Science Research Network.